LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

Search

Pfizer

Închisă

SectorSănătate

27.34 -0.11

Rezumat

Modificarea prețului

24h

Curent

Minim

27.2

Maxim

27.46

Indicatori cheie

By Trading Economics

Venit

-5.2B

-1.6B

Vânzări

903M

18B

P/E

Medie Sector

20.279

110.024

EPS

0.66

Randament dividend

6.26

Marjă de profit

-9.387

Angajați

81,000

EBITDA

-6.6B

-930M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+4.46% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

6.26%

2.26%

Următoarele câștiguri

28 apr. 2026

Data viitoare de dividende

6 mar. 2026

Următoarea dată ex-dividende

8 mai 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

5.2B

157B

Deschiderea anterioară

27.45

Închiderea anterioară

27.34

Sentimentul știrilor

By Acuity

40%

60%

135 / 351 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Bullish Evidence

Pfizer Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

3 feb. 2026, 12:25 UTC

Câștiguri

Pfizer Sales Fall on Continued Lower Covid-19 Drug Demand

20 ian. 2026, 10:40 UTC

Achiziții, Fuziuni, Preluări

GSK to Acquire RAPT for $2.2 Billion to Bolster Food Allergy Treatments -- Update

20 ian. 2026, 07:47 UTC

Achiziții, Fuziuni, Preluări

GSK to Acquire RAPT for $2.2 Billion to Bolster Food Allergy Treatments

10 feb. 2026, 21:51 UTC

Câștiguri

Gilead Earnings Surprise. Why The Stock Is Tumbling Anyway. -- Barrons.com

10 feb. 2026, 21:17 UTC

Câștiguri

Gilead Earnings Surprise. Why The Stock Is Tumbling Anyway. -- Barrons.com

3 feb. 2026, 21:36 UTC

Câștiguri

These Stocks Are Today's Movers: Palantir, Pfizer, AMD, PayPal, Novo Nordisk, PepsiCo, Merck, and More -- Barrons.com

3 feb. 2026, 19:56 UTC

Câștiguri

Pfizer Stock Falls After Solid Earnings. What's Troubling Wall Street. -- Barrons.com

3 feb. 2026, 19:46 UTC

Câștiguri

These Stocks Are Today's Movers: Palantir, Pfizer, AMD, PayPal, Novo Nordisk, PepsiCo, Merck, and More -- Barrons.com

3 feb. 2026, 17:35 UTC

Câștiguri

Pfizer Stock Falls After Solid Earnings. What's Troubling Wall Street. -- Barrons.com

3 feb. 2026, 17:30 UTC

Câștiguri

These Stocks Are Today's Movers: Palantir, PayPal, Novo Nordisk, Pfizer, Merck, AMD, Gartner, and More -- Barrons.com

3 feb. 2026, 13:50 UTC

Câștiguri

Pfizer Stock Falls After Solid Earnings. What's Troubling Wall Street. -- Barrons.com

3 feb. 2026, 13:06 UTC

Câștiguri

Pfizer Stock Falls After Solid Earnings. What's Troubling Wall Street. -- Barrons.com

3 feb. 2026, 12:45 UTC

Câștiguri

These Stocks Are Today's Movers: Palantir, PayPal, Teradyne, Tesla, Pfizer, AMD, Merck, and More -- Barrons.com

3 feb. 2026, 12:02 UTC

Câștiguri

Pfizer Stock Falls After Solid Earnings. What's Troubling Wall Street. -- Barrons.com

3 feb. 2026, 11:48 UTC

Câștiguri

Pfizer: About 20 Key Pivotal Study Starts Planned for 2026 >PFE

3 feb. 2026, 11:48 UTC

Câștiguri

Pfizer: Enters 2026 With Clear Strategic Priorities, Growing Late-Stage Pipeline >PFE

3 feb. 2026, 11:47 UTC

Câștiguri

Pfizer: Current Financial Guidance Doesn't Anticipate Any Stock Buybacks in 2026 >PFE

3 feb. 2026, 11:46 UTC

Câștiguri

Pfizer Sees 2026 Adjusted R&D Expenses $10.5B-$11.5B >PFE

3 feb. 2026, 11:45 UTC

Câștiguri

Pfizer Reaffirms 2026 Guidance >PFE

3 feb. 2026, 11:45 UTC

Câștiguri

Pfizer 4Q Rev $17.56B >PFE

3 feb. 2026, 11:45 UTC

Câștiguri

Pfizer Sees FY Adj EPS $2.80-Adj EPS $3.00 >PFE

3 feb. 2026, 11:45 UTC

Câștiguri

Pfizer 4Q Adj EPS 66c >PFE

3 feb. 2026, 11:45 UTC

Câștiguri

Pfizer 4Q Loss/Shr 29c >PFE

3 feb. 2026, 11:45 UTC

Câștiguri

Pfizer 4Q Loss $1.65B >PFE

3 feb. 2026, 11:45 UTC

Câștiguri

Pfizer Sees FY Rev $59.5B-$62.5B >PFE

3 feb. 2026, 10:41 UTC

Câștiguri

These Stocks Are Today's Movers: Palantir, Teradyne, Tesla, AMD, NXP Semiconductors, DaVita, and More -- Barrons.com

20 ian. 2026, 07:13 UTC

Achiziții, Fuziuni, Preluări

GSK PLC: Agreement Simplifies ViiV's Shareholder Structure

20 ian. 2026, 07:13 UTC

Achiziții, Fuziuni, Preluări

GSK PLC to Get Special Div of $0.250B

20 ian. 2026, 00:21 UTC

Achiziții, Fuziuni, Preluări

Shionogi to Acquire Additional Shares in ViiV Healthcare for $2.1B

12 ian. 2026, 21:18 UTC

Market Talk

Pfizer CEO Sees Large Cash Market for Obesity Drugs -- Market Talk

Comparație

Modificare preț

Pfizer Așteptări

Obiectiv de preț

By TipRanks

4.46% sus

Prognoză pe 12 luni

Medie 28.81 USD  4.46%

Maxim 35.46 USD

Minim 25 USD

În baza a 19 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruPfizer - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

19 ratings

6

Cumpărare

13

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

22.855 / 23.85Suport & Rezistență

Termen scurt

Bullish Evidence

Termen mediu

Bearish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

135 / 351 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Pfizer

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
help-icon Live chat